title: Should older adults with AML receive post-remission therapy?
abstract: The evolution of post-remission therapy in older adults has for the most part mirrored that for younger adults. However, the suitability of those regimens for an older population is less clear-cut, mainly due to poorer tolerance of therapy and a relatively higher level of disease resistance. Not only is intensive post-remission therapy not appropriate for the majority of older adults, but the role of intensive induction therapy is also unclear. Treatment goals in patients over 55-65 years differ from those in younger patients and may not necessarily be curative but life-prolonging or purely palliative. This paper reviews treatments for older AML patients in an effort to shed some light on choosing appropriate therapy.
authors.affiliation: Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D-2053, Boston, MA 02215, USA. Electronic address: rstone@partners.org.
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
mesh_terms: D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D060965:Clonal Evolution; D019468:Disease Management; D018450:Disease Progression; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010166:Palliative Care / Q000379:methods; D057285:Precision Medicine; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D012307:Risk Factors
keywords: AML; Chemotherapy; Post-remission